A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease
Status:
Terminated
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the long-term safety and tolerability of Bapineuzumab
(AAB-001, ELN115727) in subjects with Alzheimer's disease who participated in study
ELN115727-301 or study ELN115727-302.
Phase:
Phase 3
Details
Lead Sponsor:
JANSSEN Alzheimer Immunotherapy Research & Development, LLC